Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  de Araujo Souza, Patrícia S ^a,b,c   Ramanakumar, Agnihotram V ^d   Candeias, João M G ^a,e   Thomann, Patrícia ^a,f   Trevisan, Andrea ^a,g   Franco, Eduardo L ^d   Villa, Luisa L ^a,h,i  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^d MCGILL UNIVERSITY   (Canada)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f Institute of Gynaecological Cancer Research   (Brazil)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h ICESP   (Brazil)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HPV; HPV16 seropositivity; Natural antibodies; Serology

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN L2; UNCLASSIFIED DRUG; VIRAL PROTEIN; CAPSID PROTEIN; VIRUS ANTIBODY;

ADULT; AGE; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; SEXUAL BEHAVIOR; SMOKING; UTERINE CERVIX TUMOR; VIRUS IMMUNITY; VIRUS LOAD; VIRUS TYPING; ADOLESCENT; BLOOD; BRAZIL; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; SEXUALITY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BRAZIL; CAPSID PROTEINS; COHORT STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; SEXUAL PARTNERS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 84990057573     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0578-0     Document Type: Article

References (28)

1. Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 2006, 24(Suppl 1):S1-S15.
2. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM: Persistence of typespecific human papillomavirus infection among cytologically normal women. J Infect Dis 1994, 169:235-240.
3. Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL: Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008, 197:1436-1447.
4. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV: Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997, 4:122-126.
5. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD: Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004, 13:324-327.
6. Palefsky JM, Gillison ML, Strickler HD: Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006, 24(Suppl. 3):S140-S146.
7. Cid-Arregui A, Juárez V, Zur Hausen H: A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 2003, 77:4928-4937.
8. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, Morales J, Wacholder S, Guillen D, Alfaro M, Safaeian M, Burk RD, Schiffman M: A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011, 204:94-102.
9. Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J. Infect. Dis 2002, 186:737-742.
10. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-AvilaM, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339.
11. Stanley M, Pinto LA, Trimble C: Human papillomavirus vaccines-immune responses. Vaccine 2012, 30(Suppl 5):83-87.
12. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G: Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica 1999, 6:223-233.
13. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL: Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010, 70:8569-8577.
14. Ramanakumar AV, Thomann P, Candeias JM, Ferreira S, Villa LL, Franco EL: Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infection. J Clin Microbiol 2010, 48:791-796.
15. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239:487-491.
16. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM: Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991, 265:472-477.
17. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38:357-361.
18. International Agency for Research on Cancer (IARC): Human papillomaviruses. In Monographs on the evaluation of carcinogenic risks to humans, v. 90. Lyon, France: Publisher IARC; 2007.
19. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter CervicalCancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
20. Trevisan A, Schlecht NF, Ramanakumar AV, Villa LL, Franco EL: HPV16 viral load measurement as a predictor of infection clearance. J Gen Virol 2013, 94:1850-1857.
21. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL: Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003, 103:519-524.
22. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AC, Castle PE, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP: Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003, 89:1248-1254.
23. Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Wang SS, Sherman ME, Jimenez S, Solomon D, Bougelet C, Van Doorn LJ, Quint W, Safaeian M, Costa Rica HPV Vaccine Trial (CVT) Group: Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis. 2010, 37:706-714.
24. Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, Rohan TE: A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000, 9:469-476.
25. Lu B, Viscidi RP, Wu Y, Nyitray AG, Villa LL, Lazcano-Ponce E, Da Silva RJ C, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Giuliano AR: Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev 2012, 21:1542-1546.
26. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S: Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003, 103:413-421.
27. Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, Hutchinson M, Jiménez S, Sherman ME, Wacholder S, Solomon D, Van Doorn LJ, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A, Costa Rica HPV Vaccine Trial (CVT) Group: Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 2010, 10:238.
28. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC: Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002, 186:1396-1402.